ArticleFrontiers in oncology2022

Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study.

Yong Yi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.